2
|
Fizazi K. [Prostate cancer: future strategies for chemotherapy management]. ACTA ACUST UNITED AC 2008; 41 Suppl 3:S77-9. [PMID: 18297905 DOI: 10.1016/s0003-4401(07)80514-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010.
Collapse
Affiliation(s)
- K Fizazi
- Institut Gustave-Roussy, 14, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France.
| |
Collapse
|
3
|
Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI. American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. J Clin Oncol 2007; 25:5313-8. [DOI: 10.1200/jco.2007.13.4536] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PurposeIn 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.MethodsThe Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content.ResultsThe ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy.ConclusionThe review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.
Collapse
Affiliation(s)
- Ethan M. Basch
- From the Memorial Sloan-Kettering Cancer Center, New York, NY; American Society of Clinical Oncology, Alexandria, VA; Oregon Health & Science University, Portland, OR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Departments of Medicine and Urology, University of Washington, Seattle, WA; and the Ann Arbor Cancer Center, University of Michigan, Ann Arbor, MI
| | - Mark R. Somerfield
- From the Memorial Sloan-Kettering Cancer Center, New York, NY; American Society of Clinical Oncology, Alexandria, VA; Oregon Health & Science University, Portland, OR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Departments of Medicine and Urology, University of Washington, Seattle, WA; and the Ann Arbor Cancer Center, University of Michigan, Ann Arbor, MI
| | - Tomasz M. Beer
- From the Memorial Sloan-Kettering Cancer Center, New York, NY; American Society of Clinical Oncology, Alexandria, VA; Oregon Health & Science University, Portland, OR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Departments of Medicine and Urology, University of Washington, Seattle, WA; and the Ann Arbor Cancer Center, University of Michigan, Ann Arbor, MI
| | - Michael A. Carducci
- From the Memorial Sloan-Kettering Cancer Center, New York, NY; American Society of Clinical Oncology, Alexandria, VA; Oregon Health & Science University, Portland, OR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Departments of Medicine and Urology, University of Washington, Seattle, WA; and the Ann Arbor Cancer Center, University of Michigan, Ann Arbor, MI
| | - Celestia S. Higano
- From the Memorial Sloan-Kettering Cancer Center, New York, NY; American Society of Clinical Oncology, Alexandria, VA; Oregon Health & Science University, Portland, OR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Departments of Medicine and Urology, University of Washington, Seattle, WA; and the Ann Arbor Cancer Center, University of Michigan, Ann Arbor, MI
| | - Maha H.A. Hussain
- From the Memorial Sloan-Kettering Cancer Center, New York, NY; American Society of Clinical Oncology, Alexandria, VA; Oregon Health & Science University, Portland, OR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Departments of Medicine and Urology, University of Washington, Seattle, WA; and the Ann Arbor Cancer Center, University of Michigan, Ann Arbor, MI
| | - Howard I. Scher
- From the Memorial Sloan-Kettering Cancer Center, New York, NY; American Society of Clinical Oncology, Alexandria, VA; Oregon Health & Science University, Portland, OR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Departments of Medicine and Urology, University of Washington, Seattle, WA; and the Ann Arbor Cancer Center, University of Michigan, Ann Arbor, MI
| |
Collapse
|
4
|
Eymard JC, Priou F, Zannetti A, Ravaud A, Lepillé D, Kerbrat P, Gomez P, Paule B, Genet D, Hérait P, Ecstein-Fraïssé E, Joly F. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007; 18:1064-70. [PMID: 17434899 DOI: 10.1093/annonc/mdm083] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Docetaxel (Taxotere)-based regimens are the new standard therapy in advanced hormone-refractory prostate cancer (HRPC). A synergistic activity has been shown with docetaxel in combination with estramustine in vitro; however, the benefit of this combination remains controversial in clinical practice. We assessed the activity and safety of docetaxel alone and docetaxel-estramustine in HRPC. PATIENTS AND METHODS Patients (n = 92) with metastatic HRPC and rising prostate-specific antigen (PSA) while receiving androgen suppression were randomized to 3-weekly treatment with either docetaxel 75 mg/m(2), day 1 (D), or docetaxel 70 mg/m(2), day 2, plus oral estramustine 280 mg twice daily, days 1-5 (DE). RESULTS Ninety-one patients were treated (DE 47, D 44). A PSA response occurred in 68% (primary endpoint met) and 30% of patients, respectively. Median PSA response duration was 6.0 months in both groups. Median time to progression was 5.7 and 2.9 months, and median survival was 19.3 and 17.8 months in the DE and D arms, respectively. Hematologic and non-hematologic toxic effects were mild and similar in both arms. One patient in each group withdrew due to toxicity. Quality of life was similar in both groups. CONCLUSION Combining estramustine with docetaxel in this schedule is an active and well-tolerated treatment option in HRPC.
Collapse
|